REGEND-001

N/A

Report date: 2025/01/14 10:29:13

Base Information

Drug NameREGEND-001
Drug Alias Name自体肺前体细胞REGEND-001REGEND001
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Airway basal-derivedCell and gene therapy > Cell therapy > Somatic cell > Airway basal progenitor cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic ObstructiveLung Diseases, Interstitial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangxi Xianhe Medical Technology Co LtdRegend Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesRegend Therapeutics Co LtdJiangxi Xianhe Medical Technology Co LtdShanghai Rui Jin Hospital
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic ObstructiveLung Diseases, Interstitial +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A